Lesley Scott to Tuberculosis, Multidrug-Resistant
This is a "connection" page, showing publications Lesley Scott has written about Tuberculosis, Multidrug-Resistant.
Connection Strength
3,404
-
Rifampicin-resistant TB: discordance between Xpert® MTB/RIF and MTBDRplus results. Int J Tuberc Lung Dis. 2021 10 01; 25(10):832-838.
Score: 0,619
-
Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015 Jan; 75(1):91-100.
Score: 0,388
-
Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa. J Clin Microbiol. 2014 Jul; 52(7):2493-9.
Score: 0,370
-
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
Score: 0,306
-
Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
Score: 0,186
-
Cross-municipality migration and spread of tuberculosis in South Africa. Sci Rep. 2023 02 15; 13(1):2674.
Score: 0,170
-
Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization-Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis?and Resistance to Rifampicin and Isoniazid. J Mol Diagn. 2023 01; 25(1):46-56.
Score: 0,166
-
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022 02; 22(2):242-249.
Score: 0,155
-
Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid. J Clin Microbiol. 2021 02 18; 59(3).
Score: 0,148
-
Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa. Int J Tuberc Lung Dis. 2021 02 01; 25(2):134-141.
Score: 0,148
-
Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact. J Antimicrob Chemother. 2020 05 01; 75(5):1123-1129.
Score: 0,140
-
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother. 2018 10 01; 73(10):2667-2674.
Score: 0,126
-
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018 01; 18(1):76-84.
Score: 0,119
-
Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017 Jun 01; 64(11):1502-1508.
Score: 0,115
-
Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
Score: 0,087
-
False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis. 2012 Feb; 16(2):206-8.
Score: 0,079
-
Tuberculosis in east timorese refugees: implications for health care needs in East Timor. Int J Tuberc Lung Dis. 2002 Nov; 6(11):980-7.
Score: 0,042
-
Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
Score: 0,021
-
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
Score: 0,018